Olive baboons: a non-human primate model for testing dengue virus type 2 replication  by Valdés, Iris et al.
International Journal of Infectious Diseases 17 (2013) e1176–e1181Olive baboons: a non-human primate model for testing dengue virus
type 2 replication
Iris Valde´s a,1, La´zaro Gil a,1, Jorge Castro a, Damia´n Odoyo b, Rikoi Hitler b,
Elephas Munene b, Yaremis Romero a, Lucy Ochola b, Karelia Cosme a,
Thomas Kariuki b, Gerardo Guille´n a, Lisset Hermida a,*
a Center for Genetic Engineering and Biotechnology (CIGB), Avenue 31, PO Box 6162, Havana 6, 10 600, Cuba
b Institute of Primate Research (IPR), National Museum of Kenya, Nairobi, Kenya
A R T I C L E I N F O
Article history:
Received 20 May 2013
Received in revised form 23 July 2013
Accepted 7 August 2013
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Dengue
Baboons
African green monkeys
Non-human primates
Vaccine
Viremia
S U M M A R Y
Objective: This study evaluated the use of a non-human primate, the olive baboon (Papio anubis), as a
model of dengue infection. Olive baboons closely resemble humans genetically and physiologically and
have been used extensively for assessing novel vaccine formulations.
Methods: Two doses of dengue virus type 2 (DENV-2) were tested in baboons: 103 and 104 pfu. Similarly,
African green monkeys received the same quantity of virus and acted as positive controls.
Results: Following exposure, high levels of viremia were detected in both animal species. There was a
trend to detect more days of viremia and more homogeneous viral titers in animals receiving the low
viral dose. In addition, baboons infected with the virus generally exhibited positive virus isolation 1 day
later than African green monkeys. Humoral responses consisting of antiviral and neutralizing antibodies
were detected in all animals after infection.
Conclusions: We conclude that baboons provide an alternative non-human primate species for
experimental DENV-2 infection and we recommend their use for further tests of vaccines, administering
the lowest dose assayed: 103 pfu.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Dengue is the most prevalent arthropod-borne viral disease in
humans, with more than two billion people living in risk areas, and
it is estimated that there are nine million symptomatic cases and
500 000 severe episodes of dengue worldwide each year.1
The dengue illness is transmitted by the bite of mosquitoes of
the genus Aedes.2 It is caused by four antigenically related but
distinct dengue virus (DENV) serotypes (DENV-1 to DENV-4),
which belong to the family Flaviviridae, genus Flavivirus.2 Infection
with DENV results in either asymptomatic or symptomatic disease,
ranging from classical dengue fever (DF) to more severe cases of
dengue hemorrhagic fever (DHF) or dengue shock syndrome
(DSS).3 Despite the high incidence of this disease, there is currently
no vaccine to prevent the spread of dengue disease or reduce its
incidence worldwide. One of the issues that have hampered the
development of the vaccine is the lack of a suitable animal model.4* Corresponding author. Tel.: +53 7 271 6022; fax: +53 7 271 4764.
E-mail address: lisset.hermida@cigb.edu.cu (L. Hermida).
1 These authors contributed equally to the work.
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http://dx.doi.org/10.1016/j.ijid.2013.08.007Several species have been used to evaluate vaccine candidates in
preclinical studies. Although non-human primates (NHP) do not
develop the classical signs of dengue disease, this model is valuable
for studying immune responses after infection with the virus and
for evaluating several vaccine candidates.5 After virus infection,
susceptible animals develop viremia and humoral and cellular
responses, but do not exhibit the classical clinical signs observed in
humans.5 The more common species employed have been rhesus
(Macaca mulatta),6–11 cynomolgus (Macaca fascicularis),12 and New
World monkeys.13,14
In previous studies, our group demonstrated that the African
green monkey (Chlorocebus aethiops sabaeus) species is able to
provide a potential model for preclinical assessment of novel
vaccines.15,16 In these animals, the mean viremia duration with
DENV-2 was 1.6 to 5.6 days depending on the viral dose used.15 On
the other hand, when NHP were immunized with the vaccine
candidate, this viremia period was reduced.17
This present study proposed to evaluate the olive baboon (Papio
anubis) as a suitable animal model for DENV-2 infection. These
NHPs belong to the group of Old World monkeys and are widely
distributed in many parts of Africa, including northern, southern-
central, and eastern Africa.18 Their body size makes themses. Published by Elsevier Ltd. All rights reserved.
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preclinical studies,19 and for the extraction of sufﬁcient blood
volumes during the period of viremia in order to test the
parameters required for dengue vaccine assessment.
In the present study, two doses of DENV-2 were tested in
baboons: 103 and 104 plaque-forming units (pfu). Similarly, African
green monkeys received the same quantity of virus and acted as
positive controls. It was possible to isolate the virus from all
animals included in the study, and the animals developed a robust
humoral immune response after virus infection. These results
demonstrate the potential value of baboons as a model for dengue
vaccine testing.
2. Materials and methods
2.1. Animals
Healthy young adult (2–5 kg) African green monkeys (Chlor-
ocebus aethiops sabaeus) and healthy young adult (16–22 kg) olive
baboons (Papio anubis), provided by the Institute of Primate
Research (IPR, Nairobi, Kenya), were used in this study. All animals
were screened for previous exposure to DENV by ELISA and plaque
reduction neutralization test (PRNT). Animals were considered
naive when antigen-speciﬁc antibodies were undetectable by
ELISA (titer <1:50) or PRNT (titer <1:10). NHPs were maintained in
accordance with the Kenyan guidelines for the care and use of
laboratory animals, and all experimental procedures were
approved by independent scientiﬁc and ethics committees at
the IPR, Nairobi, Kenya.
2.2. Viruses
Infection was performed with a low-passage DENV-2 strain
SB8553 (Asian genotype), isolated in 2002 from a human case of DF
in Sibu, Malaysia (kindly provided by Dr M.J. Cardosa, University
Sarawak, Malaysia). Aliquots of the infection virus were stored
frozen at 80 8C at a titer of 2  106 pfu/ml. The standard strain
New Guinea C of DENV-2 was used as sucrose–acetone antigen20
for immunoassay tests.
2.3. Maintenance and clinical assessment
Animals were maintained throughout the study in individual
cages that permitted conduct patterns to be evaluated according to
the species, size, age, and sex. They were fed with commercial
monkey chow, supplemented with fruits and vegetables. Water was
available ad libitum. Infected baboons and African green monkeys
were subjected to daily clinical inspections of lymphatic ganglia,
skin, and respiratory, digestive, and nervous systems. The rectal
temperature and body weight of all animals was assessed daily by
the veterinary staff. Clinical biochemistry testing was performed on
animals on day 0 and day 30 after infection, to avoid additional stress
to the animals. These animals showed similar behavior to healthy
animals; they did not show any signs of pain or distress at any time
during the study. All results were reported and records maintained in
accordance with IPR and Kenyan guidelines for animal use in
research. The IPR follows international guidelines for the use of
animals in biomedical research, as it is a World Health Organization
Collaborating Center and has statutory registration with the NIH
Ofﬁce of Laboratory Animal Welfare, in addition to local and wide
recognition in Africa as a Center of Excellence in preclinical studies.
2.4. Virus infection and detection of viremia
Six monkeys of each species were ranked by weight, age, and
sex and then randomly divided into two groups of three animalseach. Prior to each procedure, animals were anaesthetized with an
intramuscular injection. African green monkeys were anaesthe-
tized using ketamine hydrochloride, 10 mg/kg body weight.
Baboons, due to their weight, were anaesthetized with a mixture
of ketamine hydrochloride at 10 mg/kg and xylazine hydrochloride
at 2 mg/kg body weight. Each animal was then infected
subcutaneously with 1 ml (0.5 ml in each upper arm) of virus at
doses of 103 or 104 pfu. The inoculums of 103 or 104 pfu were
obtained by diluting a preparation of 2  106 pfu/ml in RPMI-1640
medium immediately prior to infection.
Starting on day 0, 4 ml of blood was collected daily from each
animal for 11 days to detect viremia. For serological studies, the
same volumes of blood were taken at day 30 post challenge.
Animals were observed for 30 min after each inoculation for
immediate local and systemic reactions and daily for the next 10
days.
Serum from clotted blood was stored at 70 8C until viremia
was analyzed. The presence of virus in serum was determined by
inoculating 140 ml of serum diluted 1:10 onto Vero cell mono-
layers grown in 25-cm2 ﬂasks. Fresh supplemented RPMI-1640
medium (5% heat inactivated fetal bovine serum, 2 mM L-
glutamine, and 100 U of penicillin–streptomycin) was added.
The cultures were incubated for 4 h at 37 8C in a 5% CO2
atmosphere. Next, 2.5 ml of 3% medium-viscosity carboxymethyl-
cellulose was added. Plates were incubated at 37 8C for 6 days in a
5% CO2 atmosphere. To visualize the viral plaques, the monolayer
was dyed with naphthol blue black solution (naphthol blue black
0.1%, sodium acetate 0.2 M, acetic acid 6%). Viremia was
determined using the log10-transformed plaque counts detected
on Vero cells (log10 pfu/ml).
2.5. Analysis of the antibody response
The anti-DENV IgG antibodies were monitored by ELISA. Brieﬂy,
ﬂat-bottomed 96-well plates (Costar, USA) were coated with the
monoclonal antibody 4G2, which recognizes the Flavivirus E
protein,21 in coating buffer (0.16% Na2CO3, 0.29% NaHCO3, pH 9.5).
Three washes with phosphate-buffered saline (PBS) containing
0.05% Tween 20 (v:v) (PBS-T; Merck, Germany) were completed
after each step. Plates were blocked with 2% bovine serum albumin
(BSA), and then incubated overnight at 4 8C with a saturating
concentration of DENV antigen and mock antigen in separate wells.
Serially diluted samples from serum were incubated for 1 h at
37 8C with either the DENV or the mock antigen. Anti-monkey IgG-
peroxidase conjugate (Sigma, USA) was added and the plates were
incubated for 1 h at 37 8C. After washing, 0.04% substrate solution
(o-phenylenediamine in buffer 2% Na2HPO4, 1% citric acid, and 30%
H2O2, pH 5.0) was added. The plates were kept for 30 min at 25 8C
and the reaction was stopped with 12.5% H2SO4. Absorbance was
read at 492 nm in a microplate reader (SensIdent Scan; Merck,
Germany). Titers were deﬁned as the dilution of serum giving
twice the absorbance value of the negative control serum.
Antibody functionality was measured by neutralization of
DENV-2 (strain SB8553) infectivity by a PRNT on Vero cell culture
as described previously.22 The assay assessed four dilutions to
calculate the 50% plaque end-point serum titers. The neutralizing
antibody titer was identiﬁed as the highest serum dilution that
reduced the number of virus plaques by 50% and was calculated by
using a four-point linear regression method. The monoclonal
antibody 4G2 was used as positive control, which recognizes the
Flavivirus E protein.21
2.6. Statistical analysis
Data from the humoral antiviral immune response were
assessed using the non-parametric Kruskal–Wallis test and Dunn
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were analyzed by the non-parametric Mann–Whitney test. In all
cases, GraphPad Prism version 5.00 for Windows was employed
(GraphPad Software; http://www.graphpad.com).
3. Results
3.1. Physical and clinical parameters
Body temperature in all monkeys was normal throughout the
study (data not shown).
A reduction in body weight during the period of daily blood
sampling was evident for baboons (Figure 1A). The average
decrease in this group was around 1 kg of the total weight during
the ﬁrst 10 days. The degree of weight loss observed was expected
given the frequent chemical sedation undergone by the animals. At
the end of the study, the animals had completely recovered their
weight. In contrast, there was no change in the body weight of any
of the six African green monkeys during the blood sampling period
(Figure 1B).
Animals were subjected to daily clinical inspection and no
signs of physiological disturbance were detected during the
study period. All monkeys showed behavioral patterns charac-
teristic of healthy animals. Viremia was monitored from day 0 to
day 10 of infection, and the immunogenicity was assessed on day
0 and day 30.
3.2. Replication of DENV-2 in baboons and African green monkeys
The objective of this study was to compare the replicative
capacity of two viral doses of DENV-2 (103 and 104 pfu) in two(A)
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Figure 1. Changes in body weight of the animals infected with dengue virus type 2.
(A) Baboons. (B) African green monkeys. Closed symbols represent the animals
infected with 103 pfu and open symbols represent the animals infected with 104
pfu.different species of monkey. Serum samples were collected daily
from the baboons and African green monkeys infected with DENV-
2 (strain SB8553) for the detection of viremia. As shown in Table 1,
animals from both groups were able to replicate DENV-2 and
become viremic after the infection.
Typical viremia behavior was observed in all baboons, similar to
previous observations describing the use of NHPs as a model for
dengue infection. However, in this experiment the baboons
showed more homogeneous behavior compared to the African
green monkeys (Table 1).
In general, all animals developed viremia, which started at day
2–3. The viremia lasted 4 to 5 days (mean duration of 4–4.3 days)
in both species after infection with a high viral dose (104 pfu). In
baboons and African green monkeys that received the lower viral
dose, viremia lasted 4.6 and 5.7 days, respectively. Intermittent
viremia was only detected in one animal, an African green monkey
that belonged to the group infected with 104 pfu (monkey 2080)
(Table 1).
For practical and ethical reasons, a small number of animals was
used in this study, hence the results are descriptive; only general
trends were analyzed and are discussed. As shown in the Table 1,
regardless of the viral dose used, a higher viremia was observed in
baboons than in African green monkeys (1.9 log10 pfu/ml to 2.6
log10 pfu/ml vs. 1.5 log10 pfu/ml to 1.8 log10 pfu/ml, for baboons vs.
African green monkeys, respectively).
3.3. Immune responses
All animals infected with DENV-2 developed a humoral
immune response against the homologous virus measured by
ELISA and PRNT. Total IgG titers against the four serotypes were
also measured by ELISA at day 30 post infection (Table 2). For both
groups, African green monkeys and baboons, an antiviral antibody
response was developed against four serotypes, however the
highest antiviral antibody titers were observed against the
homologous serotype (p < 0.05).
When comparing the viral dose in the two animal species, the
monkeys that received the low dose elicited similar anti-DENV-2
titers (5333.3 in baboons and 6666.6 in African green monkeys),
and the same occurred in the animals receiving the highest dose
(9333.3 in baboons and 13333.3 in African green monkeys).
Similarly, both species developed similar anti-DENV-2 titers
(Table 2) regardless of the viral dose tested (GMT 7333.3 for
baboons and GMT 10000 for African green monkeys), without
statistical differences between them (p = 0.3061, by non-paramet-
ric Mann–Whitney test).
The neutralizing response was evaluated at day 30 post
infection. In contrast to the antiviral response, neutralizing titers
showed statistical differences between the species (p < 0.05).
Baboons elicited lower titers of neutralizing antibodies (GMT
471.6) compared to those developed by the African green monkeys
at the same time-point (GMT 1066.7), whatever the viral inoculum
dose (Table 3).
4. Discussion
The NHP model has been proposed as a suitable model for
dengue infection. Although these animals are not able to reproduce
all clinical symptoms of dengue disease seen in humans, they have
been used to evaluate the replication and the immune response to
vaccines.4,5 They are, however, limited by availability and expense,
as well as by safety and logistical considerations arising from
animal size, temperament, and the potential for zoonotic disease
transmission.23
In this study we evaluated the possibility of using the olive
baboon as an alternative model for DENV-2 infection. Baboons are
Table 1
Viremia after infection with dengue virus type 2 (DENV-2) in African green monkeys and baboons
Viral dose Monkey Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Total
days
Mean of
viremia
(log10
pfu/ml)
Mean of
viremic
days
Baboons DENV-2
104 pfu
3611(1) 0 0 0 1.7a 2.3 2.6 2.7 0.9 0 0 0 5 2.0 4
3614(2) 0 0 0 1.9 2.7 2.6 2.3 0 0 0 0 4 2.4
3551(3) 0 0 0 0 2.5 2. 8 2.5 0 0 0 0 3 2.6
DENV-2
103 pfu
3565(4) 0 0 0 0.9 1.8 2.2 2.7 2.4 1.7 0 0 6 2.0 4.6
3612(5) 0 0 0 0 1.7 2.4 2.6 0 0 0 0 3 2.2
3529(6) 0 0 0 1.4 2.0 2.2 2.2 1.9 0 0 0 5 1.9
African green
monkeys
DENV-2
104 pfu
2108(1) 0 0 1.3 1.3 1.9 1.8 1.4 0 0 0 0 5 1.5 4.3
2099(2) 0 0 0 0.9 1.9 2.2 2.0 0 0 0 0 4 1.7
2080(3) 0 0 1.8 1.8 1.5 0 1.2 0 0 0 0 4 1.6
DENV-2
103 pfu
2062(4) 0 0 0 1.2 2.1 2.6 1.5 0 0 0 0 4 1.8 5.7
2081(5) 0 0 0 0 1.2 2.2 2.3 2.3 1.5 1.2 0 6 1.8
2100(6) 0 0 0.9 1.5 2.2 2.0 1.5 1.2 1.2 0 0 7 1.5
a Viral detection was assessed by direct plaque formation on Vero cells.
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volumes, mainly during the viremic period. They are abundant in
Africa, and unlike African green monkeys, are not susceptible to
simian immunodeﬁciency virus infection. In addition, baboons are
more closely related to macaques than Chorocebus species,24 and
have also been used as models for other viral infections such as
West Nile virus, herpesvirus, and Rift Valley fever virus.25–27
DENV-2 infection in baboons did not change the temperature
pattern during the viremic period. Similar results have been
reported for other NHP species.5,15 Conversely, body weight during
the blood sampling period decreased more noticeably in baboons
than in African green monkeys. These differences could be
explained by the chemical agents used for the sedation procedure
in each species. While African green monkeys received only
ketamine, baboons, due to their large size, required a mixture of
the more aggressive anesthetic ketamine–xylazine to reach a
proper sedation status.28 In addition, there was a delay in food
intake by baboons after the administration of anesthesia, as
observed during daily inspections; therefore, we speculate that
this fact could be responsible for the weight loss recorded in this
species.
We also demonstrated that baboons become infected with
strain SB8553 in a similar manner to the African green monkeys
in terms of viremia duration and homogeneity. In particular,
olive baboons not only showed a viremia similar to that ofTable 2
IgG antiviral antibodies against the four serotypes from sera of baboons or African gre
Viral dose Monkey 
Baboons DENV-2 (104 pfu) 3611(1) 
3614(2) 
3551(3) 
GMT 
DENV-2 (103 pfu) 3565(4) 
3612(5) 
3529(6) 
GMT 
African green monkeys DENV-2 (104 pfu) 2108(1) 
2099(2) 
2080(3) 
GMT 
DENV-2 (103 pfu) 2062(4) 
2081(5) 
2100(6) 
GMT 
a Statistical analysis was performed by one-way analysis of variance, using the non-pa
indicate statistical differences (p < 0.05).African green monkeys, but also the viremia started at day 3 post
infection, which is an important issue in studies for dengue
vaccine testing. This initial delay in virus replication could allow
an adequate stimulation of the immunological memory induced
by a vaccine to control the viral replication. It has been reported
that the intrinsic incubation period in humans after inoculation
of the virus by the mosquito bite is 4.5 to 7 days, even exceeding
10 days in some cases.29
The ability of olive baboons to replicate DENV makes them a
suitable NHP model to study dengue infection, thus offering an
alternative to the use of macaques. The mean viremia titer (2.2
log10 pfu/ml) and duration (4.3 days) are comparable to those
described for Macaca mulatta6–11 and Macaca fascicularis,12 and are
even higher than those described for Aotus monkeys13,14 (Table 4).
The present study had a second intrinsic objective: to study
the effect of the viral dose inoculated on the magnitude of the
viremia in the two species tested. Previously, we reported that
high viral doses (106 pfu) in African green monkeys did not
increase the viremia level detected in infected animals. In this
case, an early short-term viremia was induced, as compared with
the viremia detected in monkeys receiving the low viral dose (104
pfu).15 Accordingly, in the present work, there was a trend to
detect more days of viremia and more homogeneous viral titers
in animals receiving the low viral dose, for both animal species.
Nevertheless, the observed difference between the viremiaen monkeys measured at day 30 after infection with 104 or 103 pfua
DENV-1c DENV-2b DENV-3c DENV-4bc
1600 8000 1600 1600
200 4000 400 800
3200 16 000 3200 12 800
1666.6 9333.3 1733.3 5066.6
1600 8000 800 1600
800 4000 400 800
400 4000 200 1600
933.3 5333.3 466.6 1333.3
800 8000 800 1600
400 16 000 800 1600
800 16 000 1600 6400
666.6 13 333.3 1066.6 3200
200 4000 200 400
400 8000 200 800
800 8000 400 1600
466.6 6666.6 266.6 933.3
rametric Kruskal–Wallis and Dunn multiple comparison test. Different letters (b, c)
Table 3
Neutralizing antibodies against DENV-2 in sera from baboons or African green monkeys measured at day 30 after infection. Neutralizing antibody titers are the highest serum
dilution which resulted in a 50% reduction in the number of plaques produced by DENV-2 (SB8553)a
Viral dose Monkey Neutralizing antibodies titers
Baboonsb DENV-2 (104 pfu) 3611(1) 640
3614(2) 367
3551(3) 530
GMT 512.3
DENV-2 (103 pfu) 3565(4) 640
3612(5) 331
3529(6) 322
GMT 431
African green monkeysc DENV-2 (104 pfu) 2108(1) 1280
2099(2) 640
2080(3) 1280
GMT 1066.7
DENV-2 (103 pfu) 2062(4) 640
2081(5) 1280
2100(6) 1280
GMT 1066.7
a Statistical analysis was performed using the non-parametric Mann–Whitney test. Different letters (b, c) indicate statistical differences (p < 0.05).
Table 4
Summary of the viremia data from different non-human primate species used for dengue virus type 2 replication
Monkey species Days of viremia Onset of viremia Mean of viremia (log10 pfu/ml) References
Macaca mulatta 5.7 2.5 2.1 6–11
Macaca fascicularis 5.3 2.0 - 12
Aotus nancymaae 1.7 2.2 - 13,14
Chlorocebus aethiops 5.5 2.7 1.6 15–17
Papio anubis 4.3 3.3 2.2 This article
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detected in the previously published work.15 A possible
explanation could be related to the difference between the
doses tested in the present work (1 log10) compared to that in the
previous study (2 log10).
The humoral immune response was also evaluated in this study.
The antiviral antibody response, measured by ELISA, was higher to
the homologous serotype and lower and cross-reactive to the rest
of the serotypes. Similar behavior has been observed in previous
studies conducted in macaques and African green monkeys.6,15 In
addition, there was no evident difference between the titers
obtained in the two species and even between the doses assayed.
Conversely, there were evident differences in terms of
neutralizing antibodies. Olive baboons elicited lower titers
compared to those developed by African green monkeys, whatever
the viral dose assayed. This difference was not expected since the
viremia pattern in the two species was almost the same. One
possible explanation could be a difference in the kinetics of the
neutralizing antibody response in the two species, therefore day 30
is not necessarily the best time point to compare the species. To
conﬁrm this hypothesis a kinetic study should be carried out for
the two species.
In conclusion, this study is the ﬁrst to report olive baboons as a
suitable animal model for DENV-2 infection, adding them to the list
of the few NHP species suitable for dengue vaccine testing. Studies
on the other dengue serotypes will be carried out. In addition, we
propose to evaluate the cellular immune response and the duration
of the immunity induced after infection, and consequently its
protective role upon reinfection with the same serotype, in further
studies.
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